Home » cUTI » Page 3

Tag Archives: cUTI

Progress Report: New Antibacterials In the Fight against MDR Bacteria

Posted on by — No Comments ↓

Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions about regulatory requirements, have contributed to this trend in a Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria→

Eravacycline Conference Call: Unrevealing and Disappointing

Posted on by — No Comments ↓

Whatever has become of investigative journalism?  All we read after the Stifel conference call (11/17/2015) is descriptive rehash of information provided by Tetraphase at the conference.  No probing questions that we thought investors would ask who just lost 80% of their money.  No signs of analytical or strategic readjustment at Continue reading Eravacycline Conference Call: Unrevealing and Disappointing→

After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2

Posted on by — 1 Comment ↓

When a well-designed pivotal Phase 3 trial fails to show NI, it demands an explanation.  While awaiting the company’s analysis of the data, many possible explanations are bandied about.  So it was not surprising that the eravacycline cUTI study (IGNITE-2) was mentioned quite often during ICAAC 2015, in sessions and Continue reading After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2→